Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of Berodual® Respimat® Compared to Berodual® MDI (Metered Dose Inhaler) in Asthma Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02182479
Recruitment Status : Completed
First Posted : July 8, 2014
Last Update Posted : July 14, 2014
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
Study to demonstrate that at least one of the two doses of Berodual® (50 µg fenoterol hydrobromide/20 µg ipratropium bromide and 25 µg fenoterol hydrobromide/10 µg ipratropium bromide, 1 puff q.i.d.) administered via Respimat® gives a bronchodilator response which is not inferior to that obtained from one dose of Berodual® (50 µg fenoterol hydrobromide/21 µg ipratropium bromide, 2 puffs q.i.d.) administered via MDI and that the safety profile is at least as good in asthma patients treated for 12 weeks.

Condition or disease Intervention/treatment Phase
Asthma Drug: Berodual® via Respimat®, high dose Drug: Berodual® via Respimat®, low dose Drug: Berodual® via MDI, high dose Drug: Placebo Respimat® Drug: Placebo MDI Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 631 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Comparison of the Safety and Efficacy of Berodual® Administered Via Respimat® Device (50 µg Fenoterol Hydrobromide/20 µg Ipratropium Bromide and 25 µg Fenoterol Hydrobromide/10 µg Ipratropium Bromide, 1 Puff q.i.d.) With That Administered Via the MDI (50 µg Fenoterol Hydrobromide/21 µg Ipratropium Bromide, 2 Puffs q.i.d.) in Asthma Patients Over a 12-week Period
Study Start Date : April 1998
Actual Primary Completion Date : June 1999

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Arm Intervention/treatment
Experimental: Berodual® via Respimat®, high dose Drug: Berodual® via Respimat®, high dose
Experimental: Berodual® via Respimat®, low dose Drug: Berodual® via Respimat®, low dose
Active Comparator: Berodual® via MDI, high dose Drug: Berodual® via MDI, high dose
Placebo Comparator: Placebo via Respimat® Drug: Placebo Respimat®
Placebo Comparator: Placebo via MDI Drug: Placebo MDI



Primary Outcome Measures :
  1. Change in average FEV1 (Forced expiratory volume in one second) (AUC0-6 (Area under the curve)) [ Time Frame: Pre-dose and 5, 15, 30, 60, 90, 120, 180, 240, 300, 360 minutes post-dose on day 1, 29, 57 and 85 ]

Secondary Outcome Measures :
  1. FEV1max [ Time Frame: Pre-dose and 5, 15, 30, 60, 90, 120, 180, 240, 300, 360 minutes post-dose on day 1, 29, 57 and 85 ]
  2. Time to onset of therapeutic response [ Time Frame: Days 1, 29, 57 and 85 ]
  3. Duration of therapeutic response [ Time Frame: Days 1, 29, 57 and 85 ]
  4. Time to peak FEV1 [ Time Frame: Pre-dose and 5, 15, 30, 60, 90, 120, 180, 240, 300, 360 minutes post-dose on days 1, 29, 57 and 85 ]
  5. Change in averaged weekly morning and evening pre-dose PEFR (peak expiratory flow rate) [ Time Frame: up to day 85 ]
  6. Extent of use of rescue medication [ Time Frame: up to day 85 ]
  7. Change in night-time and daytime symptom scores [ Time Frame: up to day 85 ]
  8. Overall incidence of adverse events [ Time Frame: up to day 85 ]
  9. Number of patients with clinically significant changes in Heart rate [ Time Frame: Pre-dose and 15, 30, 60, 90, 120, 180, 240, 300, 360 minutes post-dose on days 1, 29, 57 and 85 ]
  10. Number of patients with clinically significant changes in Blood pressure [ Time Frame: Pre-dose and 15, 30, 60, 90, 120, 180, 240, 300, 360 minutes post-dose on days 1, 29, 57 and 85 ]
  11. Number of patients with clinically significant changes from baseline in laboratory investigations [ Time Frame: Baseline and day 85 ]
  12. Incidence of paradoxical bronchoconstriction [ Time Frame: up to day 85 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of bronchial asthma according to the ATS (American Thoracic Society)
  • Age: 18 - 65 years
  • Screening FEV1: 40 - 80 % of predicted normal. Predicted normal values will be based on the guidelines for standardised function testing of the European Community for Coal and Steel
  • Airway obstruction reversibility: increase in FEV1 12% from baseline and ≥ 200 ml from baseline at 30 minutes after 2 puffs of Berodual® MDI
  • Current non-smoker or ex-smoker (with a smoking history of ≤ 10 pack-years) with cessation of smoking ≥ 1 year prior to the screening visit
  • Male or female patients
  • Ability to be trained in proper use of MDI and RESPIMAT® devices
  • Ability to perform technically satisfactory pulmonary function tests
  • No hospital admission for an exacerbation and stable dosage of all pulmonary medication in the last four weeks (except for long acting β2 agonists)
  • Willingness and ability to sign informed consent form prior to participation in the trial

Exclusion Criteria:

  • Patients with significant disease other than asthma, e.g. history of clinically significant cardiovascular, renal, neurological, hepatic or endocrine dysfunction. A clinically significant disease is defined as a disease which in the opinion of the investigator may either put the patient at risk because of participation in the study or which may influence the results of the study or the ability of the patient to participate in and complete the study
  • History of myocardial infarction within the last year
  • Tuberculosis with indication for treatment
  • History of cancer within the last five years, excluding treated basal cell carcinoma
  • Patients who have undergone thoracotomy for pulmonary resection of more than one bullae, or with subsequent impaired thoracic muscle performance leading to unsatisfactory lung function testing
  • Current psychiatric disorders
  • History of life threatening pulmonary obstruction, cystic fibrosis or bronchiectasis
  • An upper or lower respiratory tract infection in the four weeks prior to the screening visit (= Visit 1) or during the 2-week run-in period
  • Patients with clinically significant abnormal baseline haematology, blood chemistry or urinalysis, if the abnormality defines a disease listed as an exclusion criterion
  • Patients with AST/ALT (aspartate amino transferase/alanine amino transferase) (SGOT/SGPT (serum glutamic oxaloacetic transaminase/serum glutamic pyruvic transaminase)) > 200%, bilirubin > 150% (except isolated bilirubin increase due to Gilbert's Syndrome), or creatinine > 125% of the upper limit of the normal range
  • Intolerance to aerosolised fenoterol- or ipratropium-containing products, and/or hypersensitivity to any of the MDI ingredients
  • Patients using oral corticosteroid medication at unstable (i.e. less than 4 weeks on a stable dose) or at a dose in excess of the equivalent of 10 mg prednisone per day or 20 mg every other day
  • Beta-blocker medication
  • Patients who have taken an investigational drug one month or six half-lives (whichever is greater) prior to the screening visit
  • History of drug abuse and/or alcoholism
  • Pregnant or nursing women and women of childbearing potential or less than 2 years postmenopausal, who are not using medically approved means of contraception (oral contraceptives, intra-uterine devices or surgical Sterilisation)
  • Previous participation in this study
  • Patients who need more than 8 puffs of salbutamol (100 µg per puff) rescue medication on 3 or more consecutive days during the run-in period
  • Severe bronchial asthma with frequent nocturnal asthma attacks or acute exacerbations induced by recurrent bronchial infections several times per year
  • Patients with known hypersensitivity to anticholinergic drugs
  • Patients with known symptomatic prostatic hypertrophy or bladder neck obstruction
  • Patients with known narrow-angle glaucoma
  • Patients who did not fill in at least 80% of the diary in the run-in period for both, medication taken and peak expiratory flow rate (PEFR) measurements are considered not compliant

Layout table for additonal information
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT02182479    
Other Study ID Numbers: 215.1104
First Posted: July 8, 2014    Key Record Dates
Last Update Posted: July 14, 2014
Last Verified: July 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Fenoterol
Ipratropium
Fenoterol, ipratropium drug combination
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Sympathomimetics
Tocolytic Agents
Reproductive Control Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents